Referral to psychiatry for clonazepam or lamotrigine consideration
Substance use counseling integration
All ED encounters represent harm reduction opportunity
Brief intervention and referral to treatment (SBIRT) framework applicable
Counsel on dangers of unregulated products and wild foraging
Legal status evolving
Psilocybin decriminalized or regulated for therapeutic use in some US states and jurisdictions
ED staff should maintain non-judgmental approach to encourage honest disclosure
Patient Discharge Instructions
copy discharge instructions
What happened to you
You were treated in the emergency department for the effects of psilocybin (magic mushrooms)
These mushrooms contain a chemical called psilocybin that affects how your brain works
Symptoms typically last 4 to 6 hours and then fully go away
What to expect at home
You may feel tired or have a mild headache for 1 to 2 days
This is normal and will resolve on its own
Your mood, thoughts, and sleep may feel slightly off for 24 to 48 hours
You should NOT drive, operate machinery, or make important decisions for at least 24 hours
Return to the emergency department immediately if you experience
Confusion, hallucinations, or feeling high again after you left the hospital
This could mean a delayed reaction or a more dangerous mushroom was ingested
Severe stomach pain, vomiting, or diarrhea
This could be a sign of a dangerous mushroom poisoning called amatoxin
Amatoxin symptoms can start up to 12 hours after eating
Yellow color to your eyes or skin (jaundice)
Dark urine or not urinating
Chest pain or irregular heartbeat
Thoughts of hurting yourself
Fever, stiff muscles, or uncontrolled muscle movements
Important safety information
Never pick and eat wild mushrooms unless identified by an expert mycologist
Dangerous look-alikes can cause liver failure and death
Products labelled as psilocybin mushrooms are unregulated and may contain other substances
Do not mix mushrooms with alcohol, cannabis, other drugs, or antidepressants
Follow-up instructions
See your family doctor or a psychiatrist within 1 to 2 weeks
Especially important if you have ongoing mood changes, anxiety, or unusual thoughts
If you experience unusual persistent vision disturbances (flashbacks, visual trails, sparkles)
This can occur rarely days to weeks after use — report to your doctor
Substance use support resources
SAMHSA National Helpline: 1-800-662-4357 (free, confidential, 24/7)
Poison Control: 1-800-222-1222 for any questions about your exposure
References
Guidelines and key sources
White J, Weinstein SA, De Haro L, et al. Mushroom Poisoning: A Proposed New Clinical Classification. Toxicon. 2019
PMID 30439442
Comprehensive classification of mushroom poisoning syndromes including Group 2A (neurotoxic/psilocybin)
Leonard JB, Anderson B, Klein-Schwartz W. Does Getting High Hurt? Characterization of LSD and Psilocybin-Containing Mushroom Exposures to National Poison Centers 2000-2016. J Psychopharmacology. 2018
PMID 30182795
Demographic data: 83.9% aged 13-29; 78% male; disposition outcomes from AAPCC data
Gartner HT, Wan HZ, Simmons RE, Sollee DR, Sheikh S. Psychedelic Mushroom-Containing Chocolate Exposures: Case Series. Am J Emerg Med. 2024
PMID 39288500
19% dysrhythmia rate; IV fluids most common intervention; adulterant concern
He Z, Tang R, Feng M, et al. Dynamic Myocardial Injury and Variable Hallucination Latency in Psilocybe Keralensis Poisoning. Clin Toxicology. 2025
PMID 40948398
Molecularly confirmed case series documenting troponin elevation and variable onset timing
Malcolm B, Thomas K. Serotonin Toxicity of Serotonergic Psychedelics. Psychopharmacology. 2022
PMID 34251464
Serotonin syndrome risk stratification with SSRI and MAOI co-administration
Barnett BS, Koons CJ, Van den Eynde V, Gillman PK, Bodkin JA. Hypertensive Emergency Secondary to Combining Psilocybin Mushrooms, Extended Release Dextroamphetamine-Amphetamine, and Tranylcypromine. J Psychoactive Drugs. 2025
PMID 38903003
MAOI-psilocybin-amphetamine hypertensive emergency mechanism and management
Simon MW, Olsen HA, Hoyte CO, et al. Clinical Effects of Psychedelic Substances Reported to United States Poison Centers 2012-2022. Ann Emerg Med. 2024
PMID 39093248
Trend data showing doubling of psilocybin mushroom exposures over 10 years
Supplementary references
Hosein MM, Reid MJ, Walser S, et al. Considerations and Cautions for Integration of Psilocybin Into Routine Clinical Care. EClinicalMedicine. 2025
PMID 41048658
US National Network of Depression Centers consensus statement
Yerubandi A, Thomas JE, Bhuiya NMMA, et al. Acute Adverse Effects of Therapeutic Doses of Psilocybin: Systematic Review and Meta-Analysis. JAMA Network Open. 2024
Therapeutic dose adverse event profile
Mertens LJ, Koslowski M, Betzler F, et al. Efficacy and Safety of Psilocybin in Treatment-Resistant Major Depression. JAMA Psychiatry. 2026
Phase 3 trial data for psilocybin-assisted therapy
Mikkelsen N, Damkier P, Pedersen SA. Serotonin Syndrome — A Focused Review. Basic Clin Pharmacol Toxicol. 2023
Wennig R, Eyer F, Schaper A, Zilker T, Andresen-Streichert H. Mushroom Poisoning. Dtsch Arztebl Int. 2020
PMID 33559585
European perspective on clinical classification and amatoxin management
Shingina A, Mukhtar N, Wakim-Fleming J, et al. Acute Liver Failure Guidelines. Am J Gastroenterology. 2023
Amatoxin-induced acute liver failure management and transfer criteria
SymptomDx is an educational tool for medical professionals. It does not replace clinical judgment. Verify all clinical data and drug dosages with authoritative sources.